Furthermore, a press release confirmed that also Destiny-Breast04 met its primary endpoint, showing improved progression-free survival for patients with hormone receptor positive, HER2-low breast cancer treated with T-DXd compared to chemotherapy. Here, NR4A1 is linked to breast carcinoma.